Brinzolamide-brimonidine fixed combination for the prevention of intraocular pressure elevation after phacoemulsification.

Abstract

AIM:

To evaluate the effectiveness of brinzolamide-brimonidine fixed combination to control the intraocular pressure elevation throughout the first 24 h following uncomplicated phacoemulsification cataract surgery.

PATIENTS AND METHODS:

A total of 62 patients who underwent phacoemulsification cataract surgery were included in this prospective randomized comparative case series. The brinzolamide-brimonidine fixed combination group (34 eyes) was administered a single dose of brinzolamide-brimonidine fixed combination immediately after phacoemulsification. No treatment was administered in the control group (28 eyes). Intraocular pressure was measured 1 day before surgery (baseline) and at 6, 12 and 24 h postoperatively.

RESULTS:

The brinzolamide-brimonidine fixed combination group had significantly lower intraocular pressure at 6, 12 and 24 h after phacoemulsification compared to baseline (p < 0.0001 for all comparisons), while in control group, intraocular pressure was significantly higher at 6 and 12 h after surgery compared to baseline (p < 0.001 and p < 0.0001, respectively). In control group, an intraocular pressure elevation ⩾ 5 mm Hg was noted in 32.4% of the eyes at 6 and 12 h and in 5.9% of eyes at 24 h after surgery, while in brinzolamide-brimonidine fixed combination group, only 8.8% of the eyes at 6 h postoperatively had such an intraocular pressure elevation.

CONCLUSION:

The administration of a single drop of brinzolamide-brimonidine fixed combination effectively prevented intraocular pressure elevations and intraocular pressure spikes during the first 24 h after uneventful phacoemulsification.

• Authors: Constantine D Georgakopoulos, Konstantinos Kagkelaris, Dionysios Pagoulatos, Panagiotis Plotas, Olga E Makri
• Journal: European journal of ophthalmology (Eur J Ophthalmol) Vol. 30 Issue 2 Pg. 293-298 (Mar 2020) ISSN: 1724-6016 [Electronic] United States
• PMID: 30526051 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Adrenergic alpha-2 Receptor Agonists
• Carbonic Anhydrase Inhibitors
• Drug Combinations
• Sulfonamides
• Thiazines
• Brimonidine Tartrate
• brinzolamide

Topics

• Adrenergic alpha-2 Receptor Agonists (therapeutic use)
• Aged
• Aged, 80 and over
• Brimonidine Tartrate (therapeutic use)
• Carbonic Anhydrase Inhibitors (therapeutic use)
• Double-Blind Method
• Drug Combinations
• Female
• Humans
• Intraocular Pressure (drug effects)
• Male
• Middle Aged
• Ocular Hypertension (etiology, prevention & control)
• Phacoemulsification
• Postoperative Complications (prevention & control)
• Prospective Studies
• Sulfonamides (therapeutic use)
• Thiazines (therapeutic use)
• Tonometry, Ocular